A selective ghrelin-receptor agonist studied as a growth hormone secretagogue, with limited modern human clinical evidence. This record separates established identity and source-linked research context from protocol or commercial fields that are not yet supportable.
FEMETRIC RECORD · PUBLICIpamorelin
NeuroendocrineBody CompositionRecovery
Status
Investigational
Related
3
Sources
1
UPDATED 2026-09-13
01
Protocol references
SOURCE-LINKED
LITERATURE-DERIVED REFERENCE
Source-linked research context
No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.
Route
Intravenous research · Subcutaneous research
Frequency
See indexed source
Duration
Not indexed
Escalation
Not established
Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.
LITERATURE-DERIVED REFERENCEEuropean Journal of Endocrinology, 1998Verified 2026-09-13
Ipamorelin activates the ghrelin/growth-hormone secretagogue receptor and can stimulate GH release. Preclinical selectivity findings do not establish a body-composition protocol.
Mechanism summaries are stored with field-level source provenance for editorial audit.
07
Related research goals
08
Related peptides
01PEPTIDE
CJC-1295
A long-acting growth hormone-releasing hormone analogue studied in healthy adults for GH and IGF-1 pharmacodynamics.
NeuroendocrineBody CompositionRecovery
02PEPTIDE
Sermorelin
A GHRH(1-29) analogue formerly approved for pediatric diagnostic and treatment contexts and later discontinued commercially.
NeuroendocrineBody CompositionRecovery
03PEPTIDE
Tesamorelin
A GHRF analogue approved for reduction of excess abdominal fat in adults with HIV and lipodystrophy, with additional research contexts.